CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
14C-BI 409306drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02597998
NCT02597998Phase 1Completed
CompareCT.gov

Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration of 25 mg [14C]-BI 409306 as Oral Solution in Healthy Male Volunteers

Boehringer Ingelheim·interventional·Posted Nov 5, 2015·Updated Mar 7, 2024

In Brief

A Phase 1 clinical trial evaluating 14C-BI 409306 for Healthy. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The aim of this study is to assess the mass balance recovery from excreta of carbon 14 labelled BI409306 (\[14C\] BI 409306) in healthy, CYP2C19 genotyped subjects and to provide plasma, urine and faecal samples for metabolite profiling and structural identification.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 5, 2015
Enrollment StartSep 15, 2015
Primary CompletionDec 11, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.7 years ago

Interventions

14C-BI 409306drug